Skip to main content

Table 1 Clinical characteristics of the randomized patient groups

From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

Characteristic

977A

977B

 

Number

%

Number

%

Age at diagnosis (years)

    

   ≤ 40

89

9

80

8

   41-50

197

20

207

21

   > 50

494

51

492

50

   unknown

197

20

198

20

Distant metastasis-free survival (years)

    

   no recurrence, < 5

617

63

648

66

   recurrence, < 5

198

20

184

19

   lost to follow-up, < 5

111

11

96

10

   no recurrence, 5-to 10

245

25

253

26

   recurrence, 5 to 10

51

5

49

5

   lost to follow-up, 5 to 10

357

37

395

40

Estrogen receptor status

    

   positive

657

67

686

70

   negative

220

23

181

19

   unknown

100

10

110

11

Lymph node status

    

   negative

749

77

749

77

   positive

217

22

220

23

   unknown

11

1

8

1

Histologic grade

    

   well differentiated

105

11

131

13

   moderately differentiated

317

31

335

34

   poorly differentiated

316

32

260

27

   unknown

239

24

251

26

Tumor size (cm)

    

   ≤ 2.0

482

49

505

52

   2.1 to 5.0

363

37

356

36

   > 5.0

29

3

19

2

   unknown

103

11

97

10

Adjuvant treatment

    

   yes

478

49

488

50

   no

490

50

484

50

   tamoxifen monotherapy (ER+)

318

33

332

34

   chemotherapy

141

14

140

14

   unknown

9

1

5

1

Molecular subtypes

    

   Basal

243

25

217

22

   HER2-E

93

10

81

8

   Claudin-Low

48

5

44

5

   Luminal A

264

27

303

31

   Luminal B

185

19

188

19

  1. ER+: Estrogen receptor-positive breast cancer; HER2-E: human epidermal growth factor receptor 2-enriched.